Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 843,35 € (-0,12 %). La mediana es de 838,31 € (-0,72 %).
| Comprar |
34 |
| Mantener |
15 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Regeneron exceeds Q3 expectations significantly and hits 52-week high
Regeneron reports Q3 revenue up 36% to $5.1 billion and adjusted earnings per share of $20.07 versus $16.24 expected. Collaboration revenue with Sanofi, mainly from Dupixent, rose 68% to $2.72 billion. Strong contributions also came from Libtayo and the higher-dose Eylea, which boosted revenues by $550 million and $699 million respectively; the stock rises about 8% in premarket trading. » Más en deraktionaer.de
Regeneron highlights EYLEA HD momentum, Dupixent growth and upcoming pipeline catalysts
Regeneron reported double-digit revenue and earnings growth with EYLEA HD comprising ~60% of EYLEA franchise sales and expected low- to mid-teens sequential demand growth in Q3 and Q4 despite biosimilar pressure. Dupixent is annualizing at about $24 billion and Libtayo grew over 30% year-over-year, strengthening position in U.S. lung cancer. Management flagged near-term catalysts including an FDA decision for cemdisiran in generalized myasthenia gravis in November, PNH data in Q4, Phase III and Phase II readouts in Factor XI and MASH programs, and melanoma data later this year. The company repurchased roughly $2 billion of stock in H1 and continues to prioritize pipeline funding, business development, dividends and buybacks. » Más en finance.yahoo.com
Regeneron continues to rely on Dupixent for growth and advances pipeline and production expansion
Regeneron sees Dupixent as its main growth driver and expects about USD 22 billion for its US business in 2026, assuming a market penetration of roughly 15–20% in atopic dermatitis. EYLEA HD is gaining market share in the anti‑VEGF segment, while biosimilars are likely to intensify competition in 2026/2027. Key pipeline milestones include cemdisiran with an FDA decision for generalized myasthenia gravis in November 2026 and PNH and GA data at the end of 2026; several DUPIXENT follow‑on programs are planned. Regeneron is expanding production capacity in northern New York and is prioritizing capital allocation for internal research, selective acquisitions and share buybacks. » Más en de.investing.com
American Century sells Regeneron, cites limited upside from sluggish commercialization
American Century Investments' Focused Dynamic Growth Fund disclosed it sold its Regeneron position, saying longstanding confidence in the company's research platform has been undermined by weak commercialization of its macular degeneration treatment and limited appreciation potential. The fund redeployed proceeds into names it views as having better upside, amid a quarter where growth and AI stocks led performance while healthcare lagged. Hedge fund ownership of Regeneron also declined slightly quarter‑over‑quarter. » Más en finance.yahoo.com
Regeneron announces broad-based growth and deep pipeline at Wells-Fargo conference
At the Wells-Fargo Healthcare Conference, Regeneron presented a strategy for broader growth, stronger operational execution and an expanded product pipeline. In Q2 2026 the company recorded double-digit revenue and earnings gains, driven by record sales of EYLEA HD, DUPIXENT and LIBTAYO; DUPIXENT reached an annualized run rate of USD 24 billion. Regeneron identified several near-term catalysts, including the PDUFA date for Cemdisiran in generalized myasthenia gravis and a regulatory filing for an EYLEA-HD prefilled syringe by year-end. Management emphasized the long-term advantage of its linked genetics and proteomics database for AI-powered drug discovery and signaled openness to selective business collaborations with Sanofi at disciplined valuations. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 4516,49 M | 41,18 % |
| Beneficio bruto | 4010,08 M | 45,57 % |
| Beneficio neto | 1720,41 M | 38,28 % |
| EBITDA | 2132,7 M | 30,40 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 87,02 mil M € |
Número de acciones | 103,43 M |
Máximo/mínimo de 52 semanas | 903,67 € - 539,00 € |
Rentabilidad por dividendo | 0,37 % |
Dividendos TTM | 3,18 € |
Próximo dividendo | 0,86 € |
Beta | 0,24 |
Ratio P/E | 19,65 |
Ratio PEG | 2,41 |
Ratio P/B | 2,80 |
Ratio P/S | 5,65 |
Perfil de la empresa
Regeneron Pharmaceuticals, Inc. descubre, inventa, desarrolla, fabrica y comercializa medicamentos para el tratamiento de diversas enfermedades en todo el mundo. Los productos de la compañía incluyen EYLEA inyectable para tratar la degeneración macular asociada a la edad húmeda y el edema macular diabético; la neovascularización coroidea miópica; y la retinopatía diabética, así como el edema macular tras una oclusión de la vena retiniana, incluido el edema macular tras una oclusión de la vena central de la retina y el edema macular tras una oclusión de una rama de la vena retiniana. También ofrece Dupixent inyectable para tratar la dermatitis atópica y el asma en adultos y pacientes pediátricos; Libtayo inyectable para tratar el carcinoma epidermoide cutáneo metastásico o localmente avanzado; Praluent inyectable para la hipercolesterolemia familiar heterocigota o la enfermedad cardiovascular aterosclerótica clínica en adultos; REGEN-COV para la COVID-19; y la solución Kevzara para tratar la artritis reumatoide en adultos. Además, la compañía ofrece Inmazeb inyectable para la infección causada por el virus del Ébola de Zaire; ARCALYST inyectable para los síndromes periódicos asociados a criopirina, incluido el síndrome autoinflamatorio familiar por frío y el síndrome de Muckle-Wells; y ZALTRAP inyectable para infusión intravenosa para tratar el cáncer colorrectal metastásico; y desarrolla candidatos a medicamentos para tratar pacientes con enfermedades oculares, alérgicas e inflamatorias, cardiovasculares y metabólicas, infecciosas y raras, así como cáncer, dolor y afecciones hematológicas. Tiene acuerdos de colaboración y licencia con Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; y Kiniksa Pharmaceuticals, Ltd., y also tiene un acuerdo con el Departamento de Salud y Servicios Humanos de los Estados Unidos, así como con Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; y AstraZeneca PLC. La compañía fue fundada en 1988 y tiene su sede en Tarrytown, Nueva York.
| Nombre | Regeneron Pharmaceuticals |
| CEO | Leonard S. Schleifer |
| Sede | Tarrytown,
ny Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Biotecnología |
| Salida a bolsa | 12/09/2017 |
| Empleados | 15.410 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | REGN |
London Stock Exchange | 0R2M.L |
Frankfurt | RGO.F |
Düsseldorf | RGO.DU |
Hamburg | RGO.HM |
Milan | 1REGN.MI |
London | 0R2M.L |
SIX | RGO.SW |
München | RGO.MU |
Wien | REGN.VI |
XETRA | RGO.DE |